香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 醫學影像數據共建合作項目 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，於2025年10月，本集團之附屬公司北京一脈陽光醫學信息技術 有限公司（「北京一脈」）與北京數據先行區服務有限公司（「北京先行區」）及北京 國際算力服務有限公司（「北京算力」）共同簽署《數據共建合作協議》。北京先行區 為經北京市經濟和信息化局授權開展北京人工智能數據沙盒（「數據沙盒」）試點工 作的運營主體，負責提供數據處理、合規評審及模型訓練支持；北京算力則提供 可信存儲與算力資源等技術基礎設施。 江西一脈陽光集團股份有限公司 本次合作旨在依托數據沙盒的合規監管框架，基於 ...

Core Viewpoint - The company has entered into an investment agreement to acquire additional equity in Yinghe Medical Technology, recognizing the rapid growth potential in the medical imaging AI sector and the increasing demand for precise and efficient imaging diagnostics [1][2][3] Group 1: Investment Details - The company will invest nearly 100 million RMB to subscribe to the new registered capital of Yinghe Medical Technology, which will increase its total equity stake in the company [1] - This investment is part of the company's strategy to enhance its presence in the medical imaging AI sector, aligning with its long-term development plans [2] Group 2: Strategic Importance - The investment is expected to activate a "twin incubation" development mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a mutually beneficial growth environment [2] - By enhancing its industrial chain layout through this investment, the company aims to transition towards a data-driven service model, improving its core competitive strength in the industry [2] Group 3: Market Positioning - The investment will significantly improve the diagnostic accuracy and efficiency of the company's imaging centers and partner medical institutions, better meeting clinical needs [2] - This strategic move is anticipated to strengthen the company's position in the rapidly growing imaging AI field, allowing it to seize industry development opportunities and achieve sustained business growth [3]

Core Viewpoint - The company has signed a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1: Investment and Strategic Importance - The investment is part of the company's strategy to implement a three-in-one model of medical imaging AI, which includes medical imaging data, AI foundational models, and imaging center scenarios [2]. - This capital connection is expected to activate a "twin incubation" development mechanism, leveraging the company's accumulated quality data resources and Yinghe Medical's AI technology to create a mutually beneficial development cycle [2][3]. Group 2: Market Position and Competitive Advantage - The investment will enhance the company's industrial chain layout, improve service quality, and strengthen its competitive position in the fast-growing imaging AI field [2][3]. - By utilizing Yinghe Medical's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2]. - The anticipated outcome of this investment is to solidify the company's leadership position in China's medical imaging AI sector through the construction of a comprehensive "data + algorithm + scenario" closed-loop system [3].

Core Viewpoint - The company has entered into a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1 - The investment aligns with the company's strategy of integrating medical imaging data, AI models, and imaging center scenarios, enhancing its long-term development in the medical imaging field [2]. - The partnership with Yinghe Medical will activate a "twin incubation" mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a beneficial interaction between information, data, and AI capabilities [2]. - The investment is expected to improve the company's competitive position in the fast-growing imaging AI market, enabling sustained business growth [2][3]. Group 2 - The investment will enhance the company's layout in the medical imaging industry chain, improving the precision and efficiency of imaging diagnostic services [3]. - By utilizing Yinghe's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2][3]. - The establishment of a "data + algorithm + scenario" closed-loop system will solidify the company's leadership position in China's medical imaging AI sector [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 增資於一家醫學影像人工智能公司 本公告由江西一脈陽光集團股份有限公司（「本公司」或「一脈陽光」），連同其附屬 公司統稱（「本集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，於2025年10月29日（「簽署日」），本公司與上海影禾醫脈智能科 技有限公司（「影禾醫脈」）及其相關各方訂立《增資認購協議》（「協議」）。據此， 本公司以總代價近億元人民幣認購影禾醫脈的新增註冊資本。本次交易完成後， 本公司於影禾醫脈的持股總權益將進一步提升。 董事會認為，醫學影像人工智能作為醫療科技領域未來的核心發展方向，正迎來 市場需求快速釋放的黃金階段。隨著醫療數字化轉型加速，臨床對精準化、高效 化影像診斷的需求日益迫切，這一領域的市場空間將 ...

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Yipai Sunshine (02522.HK), indicating a slight reduction in holdings on October 27, 2025, with a decrease of 58,000 shares, representing a change of -0.05% [1][2] - Over the past five trading days, southbound funds have increased their holdings for four days, resulting in a total net increase of 1.4635 million shares [1][2] - In the last twenty trading days, there were nine days of net increases in holdings by southbound funds, totaling 245,000 shares [1][2] Group 2 - As of now, southbound funds hold 128 million shares of Yipai Sunshine, which accounts for 43.56% of the company's total issued ordinary shares [1][2] - Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China, providing imaging services and solutions [2] - The company operates three segments: imaging center services, imaging solutions, and Yipai Cloud services, supporting the development of imaging center services and data-driven operations [2]

Core Insights - The company, Yipai Sunshine (02522), announced that its subsidiary, Tianjin Yipai Yingrun Medical Imaging Diagnosis Co., successfully won the bid for the "Tianjin Beichen Hospital Medical Project" on October 24, 2025, marking a significant step in its regional strategy [1][2] - The project is expected to generate annual revenue of tens of millions, indicating substantial progress in the company's strategy of "regional deepening and national radiation" [1] - The project will establish a smart medical sharing platform comprising five modules: regional imaging sharing center, integrated smart laboratory, digital pathology center, health management center, and nuclear medicine center, enhancing resource collaboration and service efficiency [1] Company Strategy - This project represents the company's first comprehensive integration project covering imaging, testing, pathology, nuclear medicine, and health management, showcasing its capabilities in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in the North China region and lay a solid foundation for promoting similar projects in the Beijing-Tianjin-Hebei area [2] - The project is expected to have positive strategic value for the company's long-term development [2]

Core Insights - The company successfully won the bid for the "Tianjin Beichen Hospital Medical Project," marking its first government cooperative regional medical resource integration project in Tianjin, with expected annual revenue reaching tens of millions [1] - The project aims to establish a regional smart medical sharing platform, enhancing the collaboration and service efficiency of medical resources through five key modules [1] - The project reflects the company's comprehensive service capabilities in medical imaging, pathology diagnosis, and health management, gaining recognition from the government and high-end medical institutions [1] Summary by Sections - **Project Overview** - The project is a comprehensive integration initiative covering imaging, testing, pathology, nuclear medicine, and health management, showcasing the company's ability in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in North China and lay a solid foundation for similar projects in the future [2] - **Strategic Importance** - This project is a significant step in the company's "regional deep cultivation, national radiation" strategy, indicating substantial progress [1] - The innovative cooperation model will enable the company to provide standardized operational management systems and technical capabilities to assist hospitals in optimizing resources and improving efficiency [1]

Core Insights - The company, Yimai Sunshine (02522.HK), announced that its subsidiary, Tianjin Yimai Yingrun Medical Imaging Diagnosis Co., Ltd., has successfully won the bid for the "Tianjin Beichen Hospital Medical Project," marking a significant step in its strategy of regional deepening and national radiation [1][2] Group 1 - The project is expected to generate annual revenue of tens of millions, indicating substantial progress in the company's strategy [1] - The project will establish a regional smart medical sharing platform, focusing on five key modules: regional imaging sharing center, smart integrated laboratory, digital pathology center, health management center, and nuclear medicine center [1] - The Beichen Hospital, established in 1963, is a comprehensive hospital with a strong foundation in various specialties, enhancing the project's credibility and potential impact [1] Group 2 - The project represents the company's first comprehensive integration project covering imaging, testing, pathology, nuclear medicine, and health management, showcasing its capabilities in regional medical resource collaboration and smart operations [2] - The implementation of this project will strengthen the company's market presence in the North China region and lay a solid foundation for promoting similar projects in the Beijing-Tianjin-Hebei area [2] - The project is expected to have positive strategic value for the company's long-term development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會認為，該項目作為本集團首個覆蓋影像、檢驗、病理、核醫學及健康管理 的全業態整合型項目，不僅展現了本集團在區域醫療資源協同與智慧化運營方面 的整合能力，更為後續在京津冀地區推廣類似項目奠定了堅實基礎。項目的實施 將進一步強化本集團在華北地區的市場佈局，為後續拓展同類型項目奠定堅實基 礎，對本集團長期發展具有積極戰略價值。 自願公告 業務進展 中標天津市北辰醫院醫療項目 本公告由江西一脈陽光集團股份有限公司（「本公司」），連同其附屬公司統稱（「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，本公司之附屬公司天津一脈盈潤醫學影像診斷有限公司作為聯 合體牽頭方，於2025年10月24日成功中標「天津市北辰醫院醫療項目」（招標編 號：YTKX2025-B-070），並獲取中標通知書。本集團預期將聯同聯合體其他成員 於近期與天津市北辰醫院正式簽署項目合作協議。 該項目為本集團在天津地區 ...